Trial
NCT04059484
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Breast Cancer Metastatic
Intervention
Amcenestrant
Why stopped
Sponsor decision to prematurely stop the study, not linked to any safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-24